Biotech CEOs take AIM and smile

Tuesday 12 June 2007

Light regulation, low cost and flexible admission criteria make the London Stock Exchange’s Alternative Investment Market (AIM) an attractive venue for small companies that want to issue shares for the first time, according to the chief executive officers of four life science companies that have issued IPOs on AIM since 2004.

Read in full with a subscription

Learn more about subscribing to MedNous.

Subscribe